Back to stock research

Verified earnings summary

Research updated: Jul 12, 2026, 12:00 AM UTC

MRK 2026 Q1

For the quarter ended March 31, 2026, Merck reported sales growth supported by oncology, animal health, and newer launches; acquisition charges produced a quarterly loss, while management increased its full-year sales and non-GAAP EPS outlook ranges.

This page provides a source-verified release summary. It does not display a normalized metric table or post-earnings market reaction until those fields are independently verified.

Constructive signals after the release

  • Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses.
  • Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products.
  • A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.

Risks that still need monitoring

  • Keytruda concentration

    Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks.

  • Vaccine demand pressure

    Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches.

  • Business-development charges

    Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.

Primary sources

Merck Announces First-Quarter 2026 Financial ResultsMerck & Co., Inc. · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/30/2026, 12:00:00 AM

Open original source
Merck Investor RelationsMerck & Co., Inc. · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
Merck Form 10-Q for the Quarter Ended March 31, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source

Continue research

Open risk researchReturn to full stock research